Log In
BCIQ
Print this Print this
 

PUR1900

  Manage Alerts
Collapse Summary General Information
Company Pulmatrix Inc.
DescriptionDry powder formulation of an inhaled anti-infective using Pulmatrix's iSPERSE drug delivery platform
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationFungal infection
Indication DetailsTreat pulmonary fungal infections in cystic fibrosis patients
Regulatory Designation U.S. - Orphan Drug (Treat pulmonary fungal infections in cystic fibrosis patients);
U.S. - Qualified Infectious Disease Program (Treat pulmonary fungal infections in cystic fibrosis patients)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today